share_log

長江生命科技：二零二三年度全年業績

CKLIFE SCIENCES: ANNUAL RESULTS FOR 2023

香港交易所 ·  Mar 19 05:43
Summary by Moomoo AI
長江生命科技於2023年度錄得股東應佔溢利1.73億港元，較2022年的13.2億港元大幅下跌87%。此下降主要由於財務成本增加1.59億港元所致。若利率維持於2022年水平，2023年股東應佔溢利將達1.805億港元，上升約37%。過去三年，公司面對經營環境挑戰，包括通貨膨脹、勞動力短缺及供應鏈中斷等問題，但已透過提升價格、精簡營運及提高效率等措施應對。公司於2023年不建議派發末期股息。在醫療保健研發方面，公司專注於癌症治療及早期檢測方案的研發，並在治療性癌症疫苗研究取得進展。保健產品業務於2023年表現理想，溢利貢獻2.83億港元，較2022年上升8%。農業相關業務亦錄得溢利貢獻3.5億港元，增長4%。公司總資產為112.474億港元，總資產淨值為41.893億港元，相等於每股0.44港元。董事會主席李澤鉅於2024年3月19日於香港發表年度報告。
長江生命科技於2023年度錄得股東應佔溢利1.73億港元，較2022年的13.2億港元大幅下跌87%。此下降主要由於財務成本增加1.59億港元所致。若利率維持於2022年水平，2023年股東應佔溢利將達1.805億港元，上升約37%。過去三年，公司面對經營環境挑戰，包括通貨膨脹、勞動力短缺及供應鏈中斷等問題，但已透過提升價格、精簡營運及提高效率等措施應對。公司於2023年不建議派發末期股息。在醫療保健研發方面，公司專注於癌症治療及早期檢測方案的研發，並在治療性癌症疫苗研究取得進展。保健產品業務於2023年表現理想，溢利貢獻2.83億港元，較2022年上升8%。農業相關業務亦錄得溢利貢獻3.5億港元，增長4%。公司總資產為112.474億港元，總資產淨值為41.893億港元，相等於每股0.44港元。董事會主席李澤鉅於2024年3月19日於香港發表年度報告。
Changjiang Life Technologies recorded a shareholder profit of HK$1.73 billion in 2023, a significant decrease of 87% compared to HK$13.2 billion in 2022. The decrease was mainly due to an increase in financial costs of HK$1.59 million. If interest rates remain at 2022 levels, the profit attributable to shareholders in 2023 will reach HK$1.805 million, an increase of approximately 37%. Over the past three years, companies have faced environmental challenges such as inflation, labour shortages and supply chain disruptions, but have responded with measures such as raising prices, streamlining operations and improving efficiency. The company does not propose a final dividend in 2023. In healthcare R&D, the company focuses on the development of cancer treatment and early detection programs and advances in therapeutic cancer vaccine research...Show More
Changjiang Life Technologies recorded a shareholder profit of HK$1.73 billion in 2023, a significant decrease of 87% compared to HK$13.2 billion in 2022. The decrease was mainly due to an increase in financial costs of HK$1.59 million. If interest rates remain at 2022 levels, the profit attributable to shareholders in 2023 will reach HK$1.805 million, an increase of approximately 37%. Over the past three years, companies have faced environmental challenges such as inflation, labour shortages and supply chain disruptions, but have responded with measures such as raising prices, streamlining operations and improving efficiency. The company does not propose a final dividend in 2023. In healthcare R&D, the company focuses on the development of cancer treatment and early detection programs and advances in therapeutic cancer vaccine research. The healthcare products business performed well in 2023, with a profit contribution of HK$2.83 million, up 8% from 2022. Agri-related businesses also recorded a profit contribution of HK$3.5 billion, an increase of 4%. The Company's total assets are HK$112.474 billion and total net assets are HK$41.893 billion, equivalent to HK$0.44 per share. Chairman of the Board, Mr. Li, presented his Annual Report in Hong Kong on 19 March 2024.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more